Vigil Neuroscience (VIGL) to Release Quarterly Earnings on Tuesday

Vigil Neuroscience (NASDAQ:VIGL) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.08). On average, analysts expect Vigil Neuroscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vigil Neuroscience Trading Up 2.7 %

VIGL stock opened at $1.89 on Monday. The company’s 50-day moving average price is $2.35 and its 200 day moving average price is $2.73. Vigil Neuroscience has a 52 week low of $1.49 and a 52 week high of $6.06. The company has a market cap of $88.21 million, a P/E ratio of -0.92 and a beta of 1.82.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on VIGL. William Blair assumed coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They issued an “outperform” rating on the stock. Wedbush decreased their target price on Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, March 14th. JMP Securities restated a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Finally, HC Wainwright lowered their price objective on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $16.25.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.